Skip to main content

Bernstein Reaffirms Their Buy Rating on Boston Scientific (BSX)

Tipranks - Tipranks - Sat Feb 7, 6:42AM CST

Bernstein analyst Lee Hambright maintained a Buy rating on Boston Scientific yesterday and set a price target of $112.00. The company’s shares closed yesterday at $77.64.

Claim 50% Off TipRanks Premium

According to TipRanks, Hambright is a 4-star analyst with an average return of 6.4% and a 58.59% success rate. Hambright covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Insulet, and Intuitive Surgical.

In addition to Bernstein, Boston Scientific also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on February 4, TipRanks – xAI downgraded Boston Scientific (NYSE: BSX) to a Hold.

See today’s best-performing stocks on TipRanks >>

Based on Boston Scientific’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.07 billion and a net profit of $755 million. In comparison, last year the company earned a revenue of $4.21 billion and had a net profit of $469 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).